Drug name - Definity
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10022460 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(13 years from now) | |
| CN107206111B | LANTHEUS MEDCL | Lipid Encapsulated Gas Microsphere Compositions And Related Methods |
Dec, 2035
(13 years from now) | |
| CN107206111A | LANTHEUS MEDCL | Gas Microsphere Composition Of Lipid Encapsulation And Related Method |
Dec, 2035
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(13 years from now) | |
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(14 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(14 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 6.52MG/ML | INJECTABLE;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.